Extrait

To determine whether teriparatide, given as 20 mcg once daily by subcutaneous injection in postmenopausal women with osteoporosis who are at high risk for fracture, will be associated with an increase in skeletal plasma clearance of 99m Technetium methylene diphosphonate ( 99m Tc-MDP) measured from baseline to 18 months in the whole skeleton using nuclear scintigraphy.

Critère d'inclusion

• Oesteoporosis

Liens

• ictrp
• euctr